Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Granite Partners
Basel, Switzerland
- Ownership
- Private
- Development stage
- Other
01
Overview
Clinical-stage Swiss biotech developing first-in-class antibodies targeting fundamental drivers of inflammation, autoimmunity, and fibrosis. GRT-001 (pro-inflammatory monocyte depleting antibody) is in Phase 1a in healthy volunteers, with Phase 1b in IBD planned for late 2025. GRT-002 (IL-3 blocker) is in preclinical development, with trials expected in 2026.
- Therapeutic areas
- ImmunologyGastroenterologyDermatologyPulmonology
- Modalities
- Monoclonal Antibody
- Industry
- Biotech
02
Partnerships
Collaborates with Versant’s Ridgeline Discovery Engine
Beyond the preview
Go deeper on Granite Partners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Granite Partners.